Minute Insight: Abbott Receives US FDA Clearance For Spinal Cord Stimulator
Abbott announced on 19 December that the US Food and Drug Administration has approved its Eterna spinal cord stimulation system (SCS) for treating chronic pain with low-dose BURSTDR stimulation.
You may also be interested in...
News We’re Watching: Cancer Screening Partnership, New Abbott Electrophysiology Head, V-Champs AI Challenge
This week, Bioventus announced plans to sell its wound business; Pfizer and Thermo Fisher Scientific partnered to increase cancer screening access; and the FDA expanded the magnetic resonance imaging labeling for Abbott’s Eterna spinal cord stimulator.
Thornal will replace Keith Grossman who is retiring. Investors and analysts hope Thornal will help the spinal cord stimulation company reach profitability by growing its “core” chronic pain business.
VC funding will remain challenging for many in the health care industry, Silicon Valley Bank’s market manager Milo Bissin told attendees at the recent DHIS West conference. Companies focusing on promising areas such as AI-powered technologies, women’s health and value-based care likely have the best chances to draw investors’ attention.